Novo Nordisk Launches New Insulin Injection Device in US - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novo Nordisk Launches New Insulin Injection Device in US
NovePen Echo is the first insulin injection device combining half-unit dosing and memory function


Novo Nordisk has launched a new insulin injection device, NovePen Echo, in the United States. According to the company, this is the first and only pen device available in the US with half-unit dosing and a memory function that records the dose and time passed since the last injection.

The half-unit dose increments mean that patients will be able to better adjust their insulin dose, which is particularly useful for children with diabetes. In addition, 12 fun removable skins are available for a customized look, including kid-friendly designs.

"We and believe this pen can help patients fine tune their dosing while offering added reassurance they are managing their diabetes appropriately," said George McAvoy, vice president of the NovoLog brand team at Novo Nordisk, in a press statement.

Children with Diabetes founder Jeff Hitchcock stated that it is important that new, innovative tools continue to be developed so that children and caregivers have options. “NovePen Echo, which features half-unit dosing from the start and memory function, is a welcome addition to the tools children with diabetes and their caregivers have available, especially when kids are away from home."

NovePen Echo is already available in Europe, Canada and Israel.

Source: Novo Nordisk

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here